This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of irinotecan liposome II in combination with oxaliplatin and 5-FU/LV in perioperative treatment of borderline resectable pancreatic cancer in 45 patients.
According to the NCCN Clinical Practice Guidelines for Pancreatic Cancer (2024.V1 edition), patients with critically resectable pancreatic cancer.
Have at least one measurable lesion as a target lesion (according to RECIST v1.1);
Have not received any anti-tumor therapy (including radiotherapy, ablation, chemotherapy, targeting, immunotherapy, etc.) or investigational drug therapy;
ECOG: 0 ~ 1;
Pancreatic cancer of non-pancreatic ductal origin includes patients with pancreatic neuroendocrine carcinoma, pancreatic acinar cell carcinoma, pancreatic blastoma, and solid pseudopapillary tumor
Severe gastrointestinal dysfunction
Severe infection occurred within 4 weeks prior to initiation of treatment (CTCAE > Grade 2)
Blood clotting is abnormal, has a tendency to bleed, or is receiving thrombolytic or anticoagulant therapy